{"id":"NCT01634139","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2015-06","completion":"2015-12","firstPosted":"2012-07-06","resultsPosted":"2016-07-12","lastUpdate":"2016-07-12"},"enrollment":403,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Tiotropium low dose QD","otherNames":[]},{"type":"DRUG","name":"Tiotropium high dose QD","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tiotropium high dose QD","type":"EXPERIMENTAL"},{"label":"Tiotropium low dose QD","type":"EXPERIMENTAL"},{"label":"Placebo QD","type":"EXPERIMENTAL"}],"summary":"The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children (6 to 11 years old) with moderate persistent asthma.","primaryOutcome":{"measure":"FEV1 Peak (0-3h) Change From Baseline","timeFrame":"Baseline and 24 Weeks.","effectByArm":[{"arm":"Placebo Respimat","deltaMin":0.225,"sd":0.027},{"arm":"Tio R2.5","deltaMin":0.395,"sd":0.026},{"arm":"Tio R5","deltaMin":0.389,"sd":0.026}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":79,"countries":["United States","Bulgaria","Canada","Germany","Guatemala","Hungary","Latvia","Lithuania","Norway","Portugal","Romania","Russia","South Korea","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":131},"commonTop":["Asthma","Peak expiratory flow rate decreased","Nasopharyngitis","Respiratory tract infection","Respiratory tract infection viral"]}}